KineMed and CHDI Foundation Extend Huntington’s Disease Collaboration

KineMed, Inc. and CHDI Foundation, Inc. recently announced an extension of their collaboration that uses KineMed’s translational biomarker platform to characterize and track the pathogenesis of Huntington’s disease (HD) and evaluate potentially therapeutic interventions.

Contract Research Organizations To Adopt Ion Torrent Next-Generation Sequencing Platform

Two Contract Research Organizations (CROs) with leading expertise in molecular testing have decided to utilize the new Oncomine Cancer Research panel, which runs on Life Technologies Ion Torrent sequencing instruments, for clinical trial analyses and design.

Corgenix Announces CE Mark Notification for TxBCardio Assay

Corgenix Medical Corporation (OTC BB: CONX.OB) recently announced in collaboration with Randox Laboratories that Randox has been granted CE Mark notification for its TxBCardio™ Assay. The TxBCardio test measures urinary levels of the thromboxane metabolite 11dhTxB2 to determine aspirin effect in apparently healthy individuals. CE mark designation enables commercial marketing and distribution of the product in Europe.

Almac Validates Novel Test for Ovarian Cancer Patients

Almac Group Ltd.’s Diagnostics Business Unit recently announced the validated results of the ALM AADx assay, a gene expression test that identifies a subgroup of high grade serous ovarian cancer (HGSOC) patients that have a good prognosis following standard of care chemotherapy.

Thinking Big by Thinking Small: PGXL Expands its Molecular Diagnostic Capability

PGXL Technologies has formed a strategic partnership with NX PharmaGen Inc. (NXPG) to support the identification of biomarkers using their NeXosomeTM microparticle enrichment technology. Exosomes and microparticles, which are found in bodily fluids, will aid diagnosis and treatment of cancer, immunological disorders, preterm birth, diseases of the central nervous system and other medical conditions.